Subtle Medical Secures Phase II Funding for SubtleSYNTH™ Expansion
This announcement follows the recent FDA clearance of SubtleSYNTH™ for Spine STIRs.
Subtle Medical, a pioneering force in AI-driven medical imaging, has been awarded Phase II funding through the NIH SBIR grant to advance its innovative SubtleSYNTH™ technology. This new phase focuses on expanding the technology's applications to brain imaging, building on its previous success in creating synthetic STIR images for spinal imaging.
A Major Milestone in Medical Imaging
Recently, SubtleSYNTH™ reached a significant milestone by obtaining FDA clearance for generating synthetic STIR images (SynthSTIRs) from existing T1 and T2 weighted contrasts in spinal imaging. This clearance marks a crucial step forward in MRI technology, allowing for SynthSTIRs to be produced with zero acquisition time while ensuring clinical quality comparable to traditional STIR images. SubtleSYNTH™ is an essential component of Subtle Medical's growing array of AI-powered solutions, which also includes the FDA-cleared SubtleMR™ and SubtlePET™ software.
Improving MRI Efficiency
The Phase II SBIR grant will support the extension of SubtleSYNTH™ into brain imaging, addressing a significant unmet need in this area. By leveraging deep learning techniques, SubtleSYNTH™ aims to generate high-quality synthetic images without requiring extra scanning time, thereby improving the efficiency and accuracy of MRI procedures. This advancement holds promise for both patients and imaging facilities that are currently facing challenges like procedure backlogs and long wait times.
Ajit Shankaranarayanan, the Chief Product Officer at Subtle Medical, shared the company's excitement about receiving this funding. "We are delighted to have secured Phase II funding to further develop our SubtleSYNTH™ technology. This grant highlights the scientific value of our work and allows us to broaden the scope of medical imaging. With our FDA clearance for spine imaging and the support from NIH, we are ready to introduce this groundbreaking technology into brain imaging, enhancing the speed, quality, and safety of MRI examinations."
Dedication to Innovation in Medical Imaging
Subtle Medical's SubtleSYNTH™ technology has been recognized for its potential to revolutionize MRI imaging by reducing scan times and improving workflow efficiency. The recent FDA clearance for spine STIRs, along with the new Phase II SBIR grant funding, reinforces the company's commitment to advancing medical imaging through cutting-edge AI solutions.
About Subtle Medical
Subtle Medical is a leading global player in AI-driven technology focused on making medical imaging faster, safer, and more efficient. The company's advanced imaging solutions enhance radiological workflows, boosting productivity and improving patient experiences. Acknowledged as a CB Insights GenAI 50 company, Subtle Medical has also been featured multiple times on the CB Insights Top AI 100 and Digital Health 150 lists. By harnessing artificial intelligence, Subtle Medical is shaping the future of healthcare.
For more information, please visit subtlemedical.com or contact us via email at [email protected].
Frequently Asked Questions
What is Subtle Medical's recent achievement?
Subtle Medical has secured Phase II funding for its NIH SBIR grant to expand its SubtleSYNTH™ technology into brain imaging.
What technology does SubtleSYNTH™ offer?
SubtleSYNTH™ provides AI-generated synthetic STIR images, enhancing MRI efficiency and quality without requiring additional scan time.
How does the Phase II funding benefit Subtle Medical?
This funding enables Subtle Medical to further develop its SubtleSYNTH™ technology for brain imaging, addressing important needs in the medical imaging field.
Who is the Chief Product Officer of Subtle Medical?
Ajit Shankaranarayanan is the Chief Product Officer at Subtle Medical.
Where can I find more information about Subtle Medical?
For more details about Subtle Medical and its innovations, you can visit their website at subtlemedical.com.
